Foresite Capital

Dr. Michael Rome joined Foresite Capital in 2016 and leads the therapeutics investing practice. Michael previously served on the boards of (XinThera (acquired by Gilead Sciences), Affinivax (observer, acquired by GSK), Turning Point Therapeutics (observer, acquired by BMS), Pharvaris (Nasdaq: PHVS), Nurix Therapeutics (Nasdaq: NRIX, observer), and Alumis where he led the acquisition of Fronthera Biopharma. He currently serves as a board director at Kinnate Biopharma (Nasdaq: KNTE), Remix Therapeutics, Theseus Pharmaceuticals (Nasdaq: THRX), and Avenzo Therapeutics. Michael served as Vice President for Foresite Development Corporation I & II. Prior to Foresite Capital, he was an analyst at DAFNA Capital Management, covering therapeutics companies.

He earned a BS in Molecular, Cell, and Developmental Biology from UCLA and obtained his Ph.D. in Biochemistry at Caltech as an NSF Fellow.